GSK offices in Thailand and India have recently been subject to demonstrations against GSK’s patents applications for COMBID/COMBIVIR in those countries. Prior to these demonstrations GSK decided to abandon its patents and patent applications directed to a specific formulation of Combivir wherever they exist. This includes the patent applications which were the subject of the demonstrations in Thailand and India.